Literature DB >> 25682606

CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Guillaume Lefèvre1, Marie-Christine Copin2, Christophe Roumier3, Hélène Aubert4, Martine Avenel-Audran5, Nathalie Grardel3, Stéphanie Poulain3, Delphine Staumont-Sallé6, Julien Seneschal7, Gilles Salles8, Kamel Ghomari9, Louis Terriou10, Christian Leclech5, Chafika Morati-Hafsaoui11, Franck Morschhauser12, Olivier Lambotte13, Félix Ackerman13, Jacques Trauet14, Sandrine Geffroy3, Florent Dumezy3, Monique Capron15, Catherine Roche-Lestienne16, Alain Taieb7, Pierre-Yves Hatron10, Sylvain Dubucquoi14, Eric Hachulla17, Lionel Prin14, Myriam Labalette14, David Launay17, Claude Preudhomme3, Jean-Emmanuel Kahn18.   

Abstract

The CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome is characterized by hypereosinophilia and clonal circulating CD3(-)CD4(+) T cells. Peripheral T-cell lymphoma has been described during this disease course, and we observed in our cohort of 23 patients 2 cases of angio-immunoblastic T-cell lymphoma. We focus here on histopathological (n=12 patients) and immunophenotypic (n=15) characteristics of CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome. Atypical CD4(+) T cells lymphoid infiltrates were found in 10 of 12 CD3(-)CD4(+) L-HES patients, in lymph nodes (n=4 of 4 patients), in skin (n=9 of 9) and other extra-nodal tissues (gut, lacrymal gland, synovium). Lymph nodes displayed infiltrates limited to the interfollicular areas or even an effacement of nodal architecture, associated with proliferation of arborizing high endothelial venules and increased follicular dendritic cell meshwork. Analysis of 2 fresh skin samples confirmed the presence of CD3(-)CD4(+) T cells. Clonal T cells were detected in at least one tissue in 8 patients, including lymph nodes (n=4 of 4): the same clonal T cells were detected in blood and in at least one biopsy, with a maximum delay of 23 years between samples. In the majority of cases, circulating CD3(-)CD4(+) T cells were CD2(hi) (n=9 of 14), CD5(hi) (n=12 of 14), and CD7(-)(n=4 of 14) or CD7(low) (n=10 of 14). Angio-immunoblastic T-cell lymphoma can also present with CD3(-)CD4(+) T cells; despite other common histopathological and immunophenotypic features, CD10 expression and follicular helper T-cell markers were not detected in lymphoid variant of hypereosinophilic syndrome patients, except in both patients who developed angio-immunoblastic T-cell lymphoma, and only at T-cell lymphoma diagnosis. Taken together, persistence of tissular clonal T cells and histopathological features define CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome as a peripheral indolent clonal T-cell lymphoproliferative disorder, which should not be confused with angio-immunoblastic T-cell lymphoma. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25682606      PMCID: PMC5004425          DOI: 10.3324/haematol.2014.118042

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).

Authors:  G Helbig; R Wichary; M Razny; M Rodzaj; K Wozniczka; J Dziaczkowska-Suszek; S Kyrcz-Krzemien
Journal:  Scand J Immunol       Date:  2010-10       Impact factor: 3.487

2.  Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

Authors:  L Baseggio; F Berger; D Morel; M-H Delfau-Larue; G Goedert; G Salles; J-P Magaud; P Felman
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

Review 3.  Lymphoproliferative disorders associated with hypereosinophilia.

Authors:  Florence Roufosse; Soizic Garaud; Laurence de Leval
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 4.  Clinical management of the hypereosinophilic syndromes.

Authors:  Elie Cogan; Florence Roufosse
Journal:  Expert Rev Hematol       Date:  2012-06       Impact factor: 2.929

5.  Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma.

Authors:  S Serke; A van Lessen; M Hummel; A Szczepek; D Huhn; H Stein
Journal:  Cytometry       Date:  2000-06-15

Review 6.  Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.

Authors:  Laurence de Leval; Christian Gisselbrecht; Philippe Gaulard
Journal:  Br J Haematol       Date:  2009-12-04       Impact factor: 6.998

7.  The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas.

Authors:  Alessandra Stacchini; Anna Demurtas; Sabrina Aliberti; Paola Francia di Celle; Laura Godio; Giorgio Palestro; Domenico Novero
Journal:  Am J Clin Pathol       Date:  2007-11       Impact factor: 2.493

8.  Marked and persistent eosinophilia in the absence of clinical manifestations.

Authors:  Yun-Yun K Chen; Paneez Khoury; JeanAnne M Ware; Nicole C Holland-Thomas; Jennifer L Stoddard; Shakuntala Gurprasad; Amy J Waldner; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2013-08-26       Impact factor: 10.793

9.  Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features.

Authors:  J J O'Shea; E S Jaffe; H C Lane; R P MacDermott; A S Fauci
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

10.  A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.

Authors:  D Brugnoni; P Airó; G Rossi; A Bettinardi; H U Simon; L Garza; C Tosoni; R Cattaneo; K Blaser; A Tucci
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

View more
  7 in total

Review 1.  Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).

Authors:  Paneez Khoury; Praveen Akuthota; Steven J Ackerman; Joseph R Arron; Bruce S Bochner; Margaret H Collins; Jean-Emmanuel Kahn; Patricia C Fulkerson; Gerald J Gleich; Rashmi Gopal-Srivastava; Elizabeth A Jacobsen; Kristen M Leiferman; Levi-Schaffer Francesca; Sameer K Mathur; Michael Minnicozzi; Calman Prussin; Marc E Rothenberg; Florence Roufosse; Kathleen Sable; Dagmar Simon; Hans-Uwe Simon; Lisa A Spencer; Jonathan Steinfeld; Andrew J Wardlaw; Michael E Wechsler; Peter F Weller; Amy D Klion
Journal:  J Leukoc Biol       Date:  2018-04-19       Impact factor: 4.962

2.  Characterization of the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma Using Imaging Mass Cytometry.

Authors:  Ran Li; Ying Lin; Yu Wang; Shaoyuan Wang; Yang Yang; Xinlin Mu; Yusheng Chen; Zhancheng Gao
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 3.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

Review 4.  (A Critical Appraisal of) Classification of Hypereosinophilic Disorders.

Authors:  Jean Emmanuel Kahn; Matthieu Groh; Guillaume Lefèvre
Journal:  Front Med (Lausanne)       Date:  2017-12-05

5.  Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.

Authors:  Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong
Journal:  Oncotarget       Date:  2019-08-20

Review 6.  Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.

Authors:  Andrea Moerman-Herzog; Syed J Mehdi; Henry K Wong
Journal:  Cells       Date:  2020-08-29       Impact factor: 6.600

7.  Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.

Authors:  Caroline Carpentier; Sylvain Verbanck; Liliane Schandené; Pierre Heimann; Anne-Laure Trépant; Elie Cogan; Florence Roufosse
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.